ARPA-H's PROSPR program, FDA-cleared epigenetic reprogramming trials, and the XPRIZE Healthspan competition mark longevity's pivot from reversal rhetoric to evidence-led resilience, with federal capital underwriting biomarker research over consumer storytelling.